<SEC-DOCUMENT>0001178913-22-002201.txt : 20220526
<SEC-HEADER>0001178913-22-002201.hdr.sgml : 20220526
<ACCEPTANCE-DATETIME>20220526162342
ACCESSION NUMBER:		0001178913-22-002201
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220526
DATE AS OF CHANGE:		20220526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ReWalk Robotics Ltd.
		CENTRAL INDEX KEY:			0001607962
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36612
		FILM NUMBER:		22970431

	BUSINESS ADDRESS:	
		STREET 1:		3 HATNUFA ST.
		STREET 2:		FLOOR 6
		CITY:			YOKNEAM ILIT
		STATE:			L3
		ZIP:			2069203
		BUSINESS PHONE:		97249590123

	MAIL ADDRESS:	
		STREET 1:		3 HATNUFA ST.
		STREET 2:		FLOOR 6
		CITY:			YOKNEAM ILIT
		STATE:			L3
		ZIP:			2069203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Argo Medical Technologies Ltd.
		DATE OF NAME CHANGE:	20140513
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>a2227910.htm
<DESCRIPTION>DEFA 14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
      <div> <br>
      </div>
      <div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
        <div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-weight: bold;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 8-K</div>
        <div style="text-align: center; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">CURRENT REPORT</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date of Report (Date of earliest event reported): <font style="text-decoration: underline;">May 26, 2022</font></div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25; font-size: 16pt;">
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
            <div>ReWalk Robotics Ltd.<br>
            </div>
            <hr style="height: 2px; color: #000000; background-color: #000000; border: none; margin-left: auto; margin-right: auto;"></div>
        </div>
        <div style="text-align: center; line-height: 1.25;">(Exact name of registrant as specified in its charter)</div>
        <div style="text-align: center; text-indent: 36pt; line-height: 1.25;">&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf61fd2d4c6ec4a40bcc2fd37293cbdba">

            <tr>
              <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25;">Israel<br>
                </div>
              </td>
              <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25;">001-36612<br>
                </div>
              </td>
              <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25;"><font style="-sec-ix-hidden:Fact_1afd71250c6f4a5caca0ea726890786e">Not applicable</font><br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 33%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: center; line-height: 1.25;">(State or Other Jurisdiction of Incorporation)</div>
              </td>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">(Commission File Number)</div>
              </td>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">(IRS Employer Identification No.)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; line-height: 1.25;">3 Hatnufa St., Floor 6, Yokneam Ilit, Israel</div>
              </td>
              <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; line-height: 1.25;">2069203<br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
              </td>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 33%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">(Zip Code)</div>
              </td>
            </tr>

        </table>
        <div style="text-align: center; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Registrant&#8217;s telephone number, including area code: <font style="text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;+972.4.959.0123
            &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z180d44c5afda46708eb2a86aa73e7023">

            <tr>
              <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Not applicable</div>
              </td>
            </tr>

        </table>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(Former name or former address, if changed since last report)</div>
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Securities registered pursuant to Section 12(b) of the Act:</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z916faca0f59d461c90e1a89af7a751da">

            <tr>
              <td style="width: 32.01%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Title of each class</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Trading Symbol(s)</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;">
                <div style="text-align: center; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Name of each exchange on which registered</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32.01%; vertical-align: top; background-color: #CCEEFF;">
                <div style="text-align: center; line-height: 1.25;">Ordinary Shares, par value NIS 0.25<br>
                </div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: #CCEEFF;">
                <div style="text-align: justify; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: top; background-color: #CCEEFF;">
                <div style="text-align: center; line-height: 1.25;">RWLK<br>
                </div>
              </td>
              <td style="width: 2%; vertical-align: top; background-color: #CCEEFF;">
                <div style="text-align: justify; line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 32%; vertical-align: top; background-color: #CCEEFF;">
                <div style="text-align: center; line-height: 1.25;"><font style="-sec-ix-hidden:Fact_a84904f228e548be8d9c21c9eefa71ce">Nasdaq Capital Market</font><br>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br>
        </div>
        <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="font-style: italic;">see </font>General Instruction A.2. below):</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc2492217e3564431b4ff1575546d00c8">

            <tr>
              <td style="width: 3.85%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.85%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9744;<br>
                </div>
              </td>
              <td style="width: 92.31%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0e8699ff597e4ec586fbba4dad1dcdeb">

            <tr>
              <td style="width: 3.85%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#9746;<br>
              </td>
              <td style="width: 92.31%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z38aab159e25d40d3aeff7b2efaa3df1b">

            <tr>
              <td style="width: 3.85%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.85%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9744;<br>
                </div>
              </td>
              <td style="width: 92.31%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9ace03927e914f06a8f6f4a34ebd22c4">

            <tr>
              <td style="width: 3.85%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.85%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9744;<br>
                </div>
              </td>
              <td style="width: 92.31%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">&#160;<br>
          Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>
        <div style="line-height: 1.25;">&#160;&#160;</div>
        <div style="line-height: 1.25;">Emerging growth company &#9744;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
          Section 13(a) of the Exchange Act. &#9744;</div>
        <div style="font-family: 'Times New Roman',Times,serif;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="font-family: 'Times New Roman',Times,serif;">&#160;
          <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 7.01 Regulation FD Disclosure.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">On May 26, 2022, ReWalk Robotics Ltd. (the &#8220;Company&#8221;) issued a press release announcing that it filed its revised preliminary proxy with the U.S.
            Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with its 2022 Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;).&#160; In addition, the Company announced that its Board of Directors issued a letter to its shareholders, the full text
            of which is included in the press release. A copy of this press release is furnished herewith as Exhibit 99.1.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the
            Securities Exchange Act of 1934, as amended (the &#8220;1934 Act&#8221;), nor shall it be deemed &#8220;incorporated by reference&#8221; into any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as may be expressly set forth by specific
            reference in such filing.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Important Additional Information</u></div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">The Company, its directors and certain of its executive officers are participants in the solicitation of proxies from the Company&#8217;s shareholders in
            connection with the Annual Meeting. The Company intends to file a definitive proxy statement and a WHITE proxy card with the SEC in connection with any such solicitation of proxies from the Company&#8217;s shareholders. SHAREHOLDERS OF THE COMPANY
            ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. The Company&#8217;s
            definitive proxy statement for the 2021 annual meeting of shareholders contains information regarding the direct and indirect interests, by security holdings or otherwise, of the Company&#8217;s directors and executive officers in the Company&#8217;s
            securities. Information regarding subsequent changes to their holdings of the Company&#8217;s securities can be found in the SEC filings on Forms 3, 4 and 5, which are available on the Company&#8217;s website at http://ir.rewalk.com or through the SEC&#8217;s
            website at www.sec.gov. Information can also be found in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 and Amendment No. 1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 on file
            with the SEC. Updated information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the definitive proxy statement and other materials to be filed
            with the SEC in connection with the Annual Meeting. Shareholders will be able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge on
            the SEC&#8217;s website at www.sec.gov. Copies will also be available at no charge on the Company&#8217;s website at http://ir.rewalk.com.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 9.01 Financial Statements and Exhibits.</div>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z727c18ec9cb048f6afb2f376695231b6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100%; vertical-align: middle;" colspan="2">
                  <div style="line-height: 1.25;">(d) Exhibits</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5.06%; vertical-align: middle;">
                  <div style="line-height: 1.25;">99.1*</div>
                </td>
                <td style="width: 94.94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">Press release dated May 26, 2022 of ReWalk Robotics Ltd.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5.06%; vertical-align: middle;">&#160;</td>
                <td style="width: 94.94%; vertical-align: middle;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 5.06%; vertical-align: middle;">
                  <div style="line-height: 1.25;">*</div>
                </td>
                <td style="width: 94.94%; vertical-align: middle;">
                  <div style="text-align: justify; line-height: 1.25;">Furnished herewith</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <br>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SIGNATURES</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
            undersigned hereunto duly authorized.</div>
          <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z611a44f17a7a4bf8a72bfbf8673186ec">

              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="vertical-align: top;" colspan="2">
                  <div style="line-height: 1.25; font-weight: bold;">ReWalk Robotics Ltd.</div>
                </td>
                <td style="width: 12%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">Dated: May 26, 2022</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">By:</div>
                </td>
                <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="line-height: 1.25;">/s/ Almog Adar</div>
                </td>
                <td style="width: 12%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">Name:</div>
                </td>
                <td style="width: 35%; vertical-align: top;">
                  <div style="line-height: 1.25;">Almog Adar</div>
                </td>
                <td style="width: 12%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25;">Title:</div>
                </td>
                <td style="width: 35%; vertical-align: top;">
                  <div style="line-height: 1.25;">Director of Finance</div>
                </td>
                <td style="width: 12%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div id="DSPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">
            <div style="text-align: center; line-height: 1.25;">ReWalk Robotics Files Revised Preliminary Proxy Statement and </div>
            <div style="text-align: center; line-height: 1.25;">Issues Letter to Shareholders</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">Highlights the Company&#8217;s Recent Progress and Momentum Towards Value-Enhancing Commercialization </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">and Reimbursement</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">Notes that Current Board and Management Team Have the Right Skill Sets, Institutional Knowledge and </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">Third-Party Relationships to Implement Reimbursement Coverage and Create Long-Term, Sustainable </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">Value for Shareholders</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">Review of CVC Director Nominees Indicates They Would Not Add Value to the Board, Especially at this </div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">Critical Stage for the Company</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">MARLBOROUGH, Mass. BERLIN and YOKNEAM ILIT, Israel, May 26, 2022 (GLOBE NEWSWIRE) --ReWalk Robotics Ltd. (Nasdaq: RWLK)
              (&#8220;ReWalk&#8221; or the &#8220;Company&#8221;), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has filed its revised preliminary proxy statement with the U.S. Securities and Exchange
              Commission (the &#8220;SEC&#8221;). In connection with this filing, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) issued the below letter to shareholders.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">***</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">May 26, 2022</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Dear Shareholders,</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Thank you for your investment in ReWalk Robotics and your confidence in our life-changing technologies. We are writing to you
              because this year&#8217;s Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) will be especially important, as we are closing in on achieving critical milestones to pave the way for broader patient access to our solutions, which we believe will
              enhance value creation.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Your Board and management team are working hard to continue to create value by pursuing increased access to wearable robotic
              exoskeletons through expanded reimbursement coverage in the U.S. and Germany. These efforts are catalysts for achieving sustainable growth stemming from our years of thoughtful investment in research, development and innovation. In our view,
              ReWalk is at an exciting inflection point on the road to broad commercialization.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Our core strategy involves the following:</div>
            <br>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 21pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>Adding systemic coverage and reimbursement with the Centers for Medicare and
                          Medicaid (&#8220;CMS&#8221;)&#160;and other payers to improve lives and create pathways for individuals to benefit from our technologies</div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 21pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>Making meaningful progress on key long-term initiatives, including developing the
                          infrastructure for claims processing post payer approvals&#160;and to improve Veterans Affairs (&#8220;VA&#8221;) support post-COVID</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Advancing technical developments that expand our addressable markets and allow more effective penetration under existing coverage programs</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Expanding the Company product portfolio to achieve faster growth on the path to profitability</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Below we outline in further detail the exciting progress to date and our plans for the future.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">THE BOARD AND MANAGEMENT HAVE OVERSEEN TANGIBLE PROGRESS AGAINST </div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">PREVIOUSLY SET GOALS</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Your Board and management team have been focused on creating a meaningful and sustainable market for the personal use of robotic
              technologies to change patients&#8217; lives. We have made tangible progress, including the following:</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 21pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>Achieved 36% YOY revenue growth in 2021 compared to 2020, as a result of our
                          expanded sales team, increasing market access and successfully building on our contracts</div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 21pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>Built foundational clinical data and infrastructure that allowed us to obtain CMS
                          Exoskeleton code issuance and progress on coverage </div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Prioritized working with individual patient&#160;cases to establish a more efficient claims processing system in order to facilitate
                      smooth processing of cases</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 21pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>Obtained expanded Exoskeleton reimbursement coverage in Germany with two
                          additional supply agreements</div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 21pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>Added a contract with Rebotics Technology in the U.K. in order to provide the full infrastructure needed to support expansion in the U.K.</div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 21pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>Continued to drive improvements to our ReWalk Personal Exoskeleton in preparation for two different FDA submissions anticipated in 2022. These design advances
                        expand upon our position as the most used personal exoskeleton in the world and will improve functionality and usability to further increase adoption of the ReWalk Exoskeleton</div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Achieved FDA breakthrough status for two R&amp;D products that qualified for CMS coverage under the prior Medicare Coverage of Innovative Technology guidelines, and we are providing legislative support by working with the Medical Device Manufacturers Association for the Transitional Coverage of Emerging
                      Technologies coverage proposals that are intended to modify and improve the prior proposal</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Launched National Health Service pilot and made meaningful progress on our U.S. national pilot initiative for our ReStore stroke product in the U.K. and U.S.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 21pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Maintained a strong balance sheet with no debt, to support the achievement of our goals</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">WE HAVE STRONG MOMENTUM HEADING INTO THE SECOND HALF OF 2022 AND ARE </div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">APPROACHING CRITICAL MILESTONES THAT REQUIRE OUR <u>FULL BOARD&#8217;S</u> EXPERTISE AND </div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">KNOWLEDGE</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Several pivotal milestones lay ahead in the remainder of this year, and collectively we are laser-focused on leveraging the
              value-enhancing potential of these developments by:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Building on the CMS code that was achieved by defining the benefit category &#8211; with the positive development that we have been included in the June 8<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> first biannual Healthcare Common Procedure Coding System (HCPCS) session; in parallel, we will begin to submit the first Medicare cases as part of the
                      pricing and supply process in the remainder of this year</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Anticipating the issuance of a German Federal Social Court ruling that would clarify the reimbursement structure for exoskeletons and help to establish them as
                      a standard of care. This would enable the expansion of additional supply contracts</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Looking to achieve YOY revenue growth with the VA reopening post COVID-19 pandemic, German expansion and the initiation of cases with CMS</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Focusing on new business development with the potential addition of one or more commercial product lines designed to leverage our current sales pathways and
                      shorten the timeline to profitability</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">WE ARE COMMITTED TO ENSURING OUR BOARD IS CONTINUALLY REFRESHED WITH THE </div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">RIGHT MIX OF SKILL SETS AND EXPERIENCE TO OVERSEE VALUE CREATION</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We believe we have a strong Board with the necessary mix of essential skills and relevant experience to help drive our efforts to
            achieve broader reimbursement for, and commercialization of, our life-changing technologies.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">As a Board, we are focused on refreshment and evaluating on an ongoing basis whether we have the right skill sets to maximize
            value at all levels. Our commitment to Board refreshment is something we take very seriously:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div> Last month, we appointed Joseph Turk, Jr., a seasoned medical device professional with extensive experience in medical device commercialization, to the Board</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Prior to that, in October 2020, we appointed Randel Richner to the Board. Ms. Richner is a healthcare policy and reimbursement expert with over 30 years of
                      experience bringing health economics and reimbursement strategic services to the healthcare industry</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 21pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#10004;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Both Mr. Turk and Ms. Randel bring essential skill sets in reimbursement and post-CMS reimbursement, which is what we believe ReWalk needs at this critical
                      point</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Unfortunately, Creative Value Capital Limited Partnership (&#8220;CVC&#8221;), which claims to hold approximately 3% of ReWalk&#8217;s outstanding
            shares, has submitted a notice of its intent to nominate candidates for election to the Board and submit two additional proposals for consideration at the Annual Meeting.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We believe that all three of our candidates up for election at the Annual Meeting &#8211; CEO Larry Jasinski, Dr. John William Poduska
            and Randel Richner &#8211; are critical to sustaining momentum with reimbursement and technology development. Their experience and specific roles in these areas are essential to our success. CVC has provided limited information about its nominees and
            has not articulated why they should be elected to the Board. We strongly recommend that shareholders do not vote for any of CVC&#8217;s nominees.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Additionally, among CVC&#8217;s proposals is the removal of three of our sitting directors: Chairman Jeff Dykan, Yohanan Engelhardt and
            Yasushi Ichiki &#8211; all of whom bring integral and unique skill sets and experience to the Board. CVC has provided no explanation as to why it believes it would be good for our Company to remove these directors from the Board, including the
            Chairman, and we believe such removals would be detrimental to shareholders. We therefore recommend that shareholders do not support this proposal.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Despite ongoing discussions, CVC has not made a good faith attempt to work constructively with our Board, nor has it provided us
            with any suggestions for improving our business or any other insight into how its nominees would enhance value for all shareholders. As a result, our Board cannot and does not endorse any of the shareholder nominees. However, we remain open to
            a continued dialogue in order to avoid a costly, distracting and unnecessary proxy contest that threatens our trajectory.</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Thank you for your support.</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Sincerely,</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">Jeff Dykan, Chairman</div>
                  <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                </td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">Arik Dan</div>
                </td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">Yohann Engelhardt</div>
                </td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">Yasushi Ichiki</div>
                  <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                </td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">Larry Jasinski</div>
                  <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                </td>
              </tr>
              <tr>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">Dr. John William Poduska</div>
                </td>
                <td style="width: 20%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">Randel Richner</div>
                </td>
                <td style="width: 20%; vertical-align: middle;">
                  <div style="text-align: center; line-height: 1.25;">Joseph Turk</div>
                </td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">Wayne B. Weisman</div>
                </td>
                <td style="width: 20%; vertical-align: top;">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">***</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>About&#160;ReWalk Robotics Ltd.</u></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb
              disabilities as a result of spinal cord injury or stroke.&#160; ReWalk&#8217;s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies.
              Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit <u>rewalk.com</u></div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ReWalk&#174; and ReStore&#174; are registered trademarks of ReWalk Robotics Ltd. in the United States and other
              jurisdictions.<br style="line-height: 1.25;">
              <br>
                <u>Forward Looking Statements</u></div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S.
              Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future
              performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan,"
              "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to
              uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the
              forward-looking statements include, among others: uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the
              adverse effect that the COVID-19 pandemic has had and may continue to have on the Company&#8217;s business and results of operations; ReWalk's ability to have sufficient funds to meet certain future capital requirements, which could impair the
              Company's efforts to develop and commercialize existing and new products; ReWalk's ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if
              it cannot do so; ReWalk&#8217;s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to achieve reimbursement from third-party payors, including CMS, for its products; ReWalk's limited operating
              history and its ability to leverage its sales, marketing and training infrastructure; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's expectations regarding future growth, including its ability to
              increase sales in its existing geographic markets and expand to new markets; ReWalk's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; ReWalk's ability to
              improve its products and develop new products; ReWalk's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions
              such as mandatory recalls, and the potential impact of such adverse events on ReWalk's ability to market and sell its products; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to maintain adequate protection of
              its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; ReWalk's ability to use
              effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in ReWalk's annual report on Forms 10-K and 10-K/A for the year ended December 31, 2021 filed with the SEC and other
              documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements
              contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new
              information, future developments or otherwise.</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Important Additional Information</u></div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">The Company, its directors and certain of its executive officers are participants in the solicitation of proxies from the
            Company&#8217;s shareholders in connection with the Annual Meeting. The Company intends to file a definitive proxy statement and a WHITE proxy card with the SEC in connection with any such solicitation of proxies from the Company&#8217;s shareholders.
            SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT
            INFORMATION. The Company&#8217;s definitive proxy statement for the 2021 annual meeting of shareholders contains information regarding the direct and indirect interests, by security holdings or otherwise, of the Company&#8217;s directors and executive
            officers in the Company&#8217;s securities. Information regarding subsequent changes to their holdings of the Company&#8217;s securities can be found in the SEC filings on Forms 3, 4 and 5, which are available on the Company&#8217;s website at
            http://ir.rewalk.com or through the SEC&#8217;s website atwww.sec.gov. Information can also be found in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 and Amendment No. 1 to the Company&#8217;s Annual Report on Form 10-K for
            the year ended December 31, 2021 on file with the SEC. Updated information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the definitive proxy
            statement and other materials to be filed with the SEC in connection with the Annual Meeting. Shareholders will be able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by
            the Company with the SEC at no charge on the SEC&#8217;s website at www.sec.gov. Copies will also be available at no charge on the Company&#8217;s website at http://ir.rewalk.com.</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Contacts</u></div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Investors:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Morrow Sodali</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Michael Verrechia / Eric Kamback, 203-658-9400</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>m.verrechia@morrowsodali.com</u> / <u>e.kamback@morrrowsodali.com</u></div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Media:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Longacre Square Partners</div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Joe Germani / Greg Marose</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>jgermani@longacresquare.com</u> / <u>gmarose@longacresquare.com</u></div>
          <br>
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
